Protara Therapeutics, Inc. (TARA) › Cash & EquivalentsProtara Therapeutics, Inc. (TARA) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2011-12-31: $3.27M2012-12-31: $2.41M2013-12-31: $2.79M2014-12-31: $68.84M2015-12-31: $40.03M2016-12-31: $36.39M2017-12-31: $21.17M2018-12-31: $19.37M2019-12-31: $564.0K2020-12-31: $168.60M2021-12-31: $35.72M2022-12-31: $24.13M2023-12-31: $39.59M2024-12-31: $162.80M2025-12-31: $49.66M$49.66M2011-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$49.66M-69.5%2026-03-10Balance as of period end2024-12-31$162.80M+311.3%2026-03-10Balance as of period end2023-12-31$39.59M+64.1%2025-03-05Balance as of period end2022-12-31$24.13M-32.5%2024-03-13Balance as of period end2021-12-31$35.72M-78.8%2023-03-08Balance as of period end2020-12-31$168.60M+29793.3%2022-03-09Balance as of period end2019-12-31$564.0K-97.1%2021-03-11Balance as of period end2018-12-31$19.37M-8.5%2020-03-20Balance as of period end2017-12-31$21.17M-41.8%2019-03-13Balance as of period end2016-12-31$36.39M-9.1%2018-03-14Balance as of period end2015-12-31$40.03M-41.8%2018-03-14Balance as of period end2014-12-31$68.84M+2364.7%2018-03-14Balance as of period end2013-12-31$2.79M+15.9%2017-03-16Balance as of period end2012-12-31$2.41M-26.3%2016-03-14Balance as of period end2011-12-31$3.27M—2015-03-20Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)